Αρχική World News Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy for...

Fragment Analysis Is a More Reliable MET Exon 14 Screening Strategy for Identifying Large Deletions

Comparison of two techniques used in screening non-small cell lung cancer (NSCLC) tumour samples demonstrated that fragment analysis could detect large MET exon 14 skipping deletions that were missed by next-generation sequencing (NGS), according to findings presented at the MAP 2020 Virtual Congress.

Lead author Romain Loyaux and colleagues from the Molecular Oncology Department, Hopital Europeen Georges-Pompidou – APHP in Paris, France conducted this study to evaluate the utility of NGS compared with fragment analysis for the detection of MET exon 14 alterations, including skipping deletions that act as an oncogenic driver and are observed in 1 to 4% of NSCLC tumours.

Capmatinib (Tabrecta, Novartis) was recently approved by the US Food and Drug Administration for management of adult patients with metastatic NSCLC with MET exon 14 skipping mutations, making detection of MET alterations needed to identify candidates for the treatment with capmatinib.

In addition, MET exon 14 mutations may serve as a marker of low response rates to treatment with immune checkpoint inhibitor therapy, despite high tumour PD-L1 expression.

NGS failed to detect two large MET exon 14 skipping deletions and may provide false negative results

The investigators examined 87 NSCLC wild-type samples for MET exon 14 by NGS and fragment analysis that were obtained in routine settings within an 18-month period from patients with driver wild-type NSCLC.

MET exon 14 skipping was screened by fragment analysis to detect large deletions in MET exon 14 and by DNA NGS on a Ion Proton plateform using ampliseq technology. Large deletions detected by only fragment analysis were also characteriesed by Sanger sequencing. PD-L1 tumour expression was quantified by immunohistochemistry.

Of the 87 patient samples evaluated by fragment analysis and sequencing, a MET exon 14 skipping alteration was detected in 13 patients. Among the 13 patients, eight samples had deletion impacting splice site and five had splice variants. Among the eight deletions, two were large deletions of 41 bp and 66 bp. These two deletions were only determined by fragment analysis and were not detected by NGS.

Fragment-Analysis-Is-a-More-Reliable-MET-Exon-14-Screening-Strategy-for-Identifing-Large-Deletions

a) Diagnostic algorithm to screen all MET Exon 14 mutations; b) Results and description of the 13 MET Exon 14 positive samples. The two deletions of 41 and 66 bp are only detected by fragment analysis and are described on 5′ and 3′ ends of MET.

© Romain Loyaux.

Histologically, there was no enrichment in samples with sarcomatoid features.

However, an association with PD-L1 expression was observed; samples with MET exon 14 skipping presented higher values of PD-L1 than other tumours screened in this study.

Conclusions

Detection of MET alterations is warranted for first-line treatment decision to detect exon 14 skipping and allow patient access to targeted therapy, such as capmatinib, as well as to identify patients that may have a poor response to immunotherapy, according to the authors. They concluded that these results highlight the limit of NGS to analyse large deletions and the risk of false negative results.

This study underscores that NGS, using standard pipelines and panels, may fail to detect MET exon 14 mutations. Association of complementary methods or large coverage intron screening could be alternatively used in order not to miss samples with MET alterations that could impair first-line treatment choices in patients with NSCLC.

The link between MET exon 14 and PD-L1 expression warrants further study.

No external funding was disclosed for this study.

Reference

4MO – Loyaux R, Blons H, Garinet S, et al. MET exon 14 screening strategy, how not to miss large deletions. MAP 2020 Virtual Congress (9-10 October 2020).

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...

ΠΑΓΚΟΣΜΙΑ ΗΜΕΡΑ ΚΑΡΚΙΝΟΥ

Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic Assessment in Metastatic Non-Seminomatous Germ Cell Tumours

A new web-based calculator based on the results of the International Germ Cell Cancer Collaborative Group (IGCCCG) Update analysis allows improved and more granular individual prognostic...

How Sharing My Story Helps Me Cope With an Advanced Brain Tumor Diagnosis

Tom Freeman is an audio technology professional working in Silicon Valley. At night, he is a music and video producer who works with various...

Percentage of Cancer Patients Who Are Eligible for and Respond to Genome-Targeted Therapy Modestly Increased Over Time

Dr. Alyson Haslam of the Department of Epidemiology and Biostatistics, University of California San Francisco in San Francisco, CA, US and colleagues reported on...

How to Find an Oncologist Who’s an LGBTQ+ Ally: An Expert Q&A

Charles Kamen, PhD, MPH, is a clinical psychologist and assistant professor at the University of Rochester Medical Center. Dr. Kamen has a strong background...

Sharing Energy

Do you have a favorite flower? It is very difficult for me to choose a favorite, for there is such a vast array of...

FDA Approves BCMA-Targeted CAR T-Cell Therapy for Multiple Myeloma

April 14, 2021, by NCI Staff Manufactured CAR T cells ready for infusion into a patient. Credit: Penn Medicine A type of immunotherapy called CAR T-cell therapy...